Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Marathon Digital Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.2 (market cap $39.89B), while Marathon Digital Holdings Inc trades at $12.27 (market cap $4.80B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 8.3× Marathon Digital Holdings Inc's market cap, and Marathon Digital Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MARA | |
|---|---|---|
Market Cap | $39.89B | $4.80B |
Sector | Health | Technology |
52-Week High | $491.22 | $22.84 |
52-Week Low | $278.09 | $6.73 |
Enterprise Value | $38.15B | $6.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MARA Holdings trades at $12.60, down 4.69% on the day, amid mixed signals. The stock shows a bullish technical trend with strong support at $12, while fundamentals reveal deep losses with a net income margin of -234.83% in 2026. Recent news highlights a strategic pivot to AI infrastructure, including a Texas land acquisition adding 2 GW power capacity, driving investor optimism despite earnings misses.
Outlook hinges on successful execution of AI data center expansion, offering growth potential but carrying high execution risk. Analysts maintain a $17.88 price target (50% buy rating), yet persistent cash burn and competitive pressures pose significant downside risks. Stock appears speculative, balancing transformative opportunities against substantial financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
